Long-term treatment with a beta-blocker timolol attenuates renal-damage in diabetic rats via enhancing kidney antioxidant-defense system
- 395 Downloads
The factors with increasing diabetes-prevalence lead to significant global increases in chronic kidney disease. Since hyperglycemia generates more ROS and attenuates cellular antioxidant-defense mechanisms, numerous studies demonstrated that hyperglycemia-induced oxidative stress played a major role in the extracellular matrix expansion in tissues. Although no direct relation between activation of beta-adrenergic (β-AR) system and kidney disease in diabetes and since β-blockers demonstrate marked beneficial effects due to their scavenging free radicals and/or acting as an antioxidant in diabetic animal studies, the eventual objective of the present study was to determine whether timolol-treatment of streptozotocin-induced diabetic rats (5 mg/kg, daily following diabetes-induction, for 12-week) has advantage to prevent hyperglycemia-induced renal-damage via enhancing the depressed antioxidant defense in the kidney. Light microscopy data and their quantification demonstrated that timolol-treatment prevented basically glomerular hypertrophy, expansion in mesangium cell size, thickening and fibrosis in glomerular basement membrane, and accumulation of glycogen into tubular epithelial cells. Additionally, electron microscopy data demonstrated that timolol-treatment could also prevent diabetes-induced changes in the kidney tissue such as hypertrophy in podocytes, lost of filtration gaps and slit-diaphragms, and vacuolization in the distal tubular cells. Biochemical analysis basically on enzymes of antioxidant-defense system, including glutathione-S-transferase, glutathione reductase, and glucose-6-phosphate dehydrogenase, further supported that diabetes-induced damage in the kidney is mostly dependent on the increased oxidative stress and timolol, having an antioxidant-like action, could protect the kidney against hyperglycemia-induced damage without normalization of high-blood glucose level. Consequently, it can be suggested that although β-blockers are widely used for the treatment of cardiovascular diseases, β-blocker therapy of diabetics seems to be a new therapeutic approach against hyperglycemia-induced kidney damage in diabetic patients.
KeywordsDiabetes Antioxidants Beta-blockers Kidney
This work has been supported partially by grant from TUBITAK SBAG-111S042.
Conflicts of interest
No potential conflicts of interest relevant to this article were reported.
- 6.Palsamy P, Subramanian S (2009) Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats. Chem Biol Interact 179(2–3):356–362. doi: 10.1016/j.cbi.2008.11.008S0009-2797(08)00626-1 PubMedCrossRefGoogle Scholar
- 7.Prasath GS, Subramanian SP (2011) Modulatory effects of fisetin, a bioflavonoid, on hyperglycemia by attenuating the key enzymes of carbohydrate metabolism in hepatic and renal tissues in streptozotocin-induced diabetic rats. Eur J Pharmacol 668(3):492–496. doi: 10.1016/j.ejphar.2011.07.021S0014-2999(11)00796-5 PubMedCrossRefGoogle Scholar
- 11.Tangri N, Shastri S, Tighiouart H, Beck GJ, Cheung AK, Eknoyan G, Sarnak MJ (2011) Beta-Blockers for prevention of sudden cardiac death in patients on hemodialysis: a propensity score analysis of the HEMO Study. Am J Kidney Dis 58(6):939–945. doi: 10.1053/j.ajkd.2011.06.024S0272-6386(11)01072-9 PubMedCrossRefGoogle Scholar
- 13.Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY, Wu KD, Tu YK, Chien KL (2013) Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ 347:f6008. doi: 10.1136/bmj.f6008bmj.f6008 PubMedCentralPubMedCrossRefGoogle Scholar
- 14.Yasuda G, Yatsu K, Yamamoto Y, Hirawa N (2012) Effects of carvedilol as third-line add-on therapy on blood pressure and glucose metabolism in type 2 diabetic patients with chronic renal disease stage 3 and above. Kidney Blood Press Res 36(1):131–138. doi: 10.1159/000341491000341491 PubMedCrossRefGoogle Scholar
- 16.Miyamoto N, Izumi H, Miyamoto R, Kubota T, Tawara A, Sasaguri Y, Kohno K (2009) Nipradilol and timolol induce Foxo3a and peroxiredoxin 2 expression and protect trabecular meshwork cells from oxidative stress. Invest Ophthalmol Vis Sci 50(6):2777–2784. doi: 10.1167/iovs.08-3061iovs.08-3061 PubMedCrossRefGoogle Scholar
- 17.Mochizuki M, Yano M, Oda T, Tateishi H, Kobayashi S, Yamamoto T, Ikeda Y, Ohkusa T, Ikemoto N, Matsuzaki M (2007) Scavenging free radicals by low-dose carvedilol prevents redox-dependent Ca2+ leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol 49(16):1722–1732. doi: 10.1016/j.jacc.2007.01.064 PubMedCrossRefGoogle Scholar
- 27.Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D’Agati VD, Schmidt AM (2003) RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162(4):1123–1137. doi: 10.1016/S0002-9440(10)63909-0 PubMedCentralPubMedCrossRefGoogle Scholar
- 28.Habibi J, Hayden MR, Sowers JR, Pulakat L, Tilmon RD, Manrique C, Lastra G, Demarco VG, Whaley-Connell A (2011) Nebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats. Endocrinology 152(2):659–668. doi: 10.1210/en.2010-1038en.2010-1038 PubMedCentralPubMedCrossRefGoogle Scholar
- 29.Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, Jankowski M, Martyniec L, Angielski S, Malinski T (2003) Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 107(21):2747–2752. doi: 10.1161/01.CIR.0000066912.58385.DE01.CIR.0000066912.58385.DE PubMedCrossRefGoogle Scholar
- 33.Fujii S, Sawa T, Ihara H, Tong KI, Ida T, Okamoto T, Ahtesham AK, Ishima Y, Motohashi H, Yamamoto M, Akaike T (2010) The critical role of nitric oxide signaling, via protein S-guanylation and nitrated cyclic GMP, in the antioxidant adaptive response. J Biol Chem 285(31):23970–23984. doi: 10.1074/jbc.M110.145441M110.145441 PubMedCentralPubMedCrossRefGoogle Scholar